(Bloomberg) -- EssilorLuxottica SA agreed to buy the streetwear label Supreme from VF Corp. for $1.5 billion in cash, adding another lifestyle brand to the French-Italian eyewear company’s stable that already includes Ray-Ban and Oakley. Most Read from Bloomberg BlackRock Says Gunman From Trump Rally Appeared in Firm’s Ad Trump Security Tightened on Iran Plot Intel; No Link to Shooting US Floats Tougher Trade Curbs in Chip Crackdown on China Amazon Sold a Used Diaper. It Tanked a Mom-and-Pop Business HSBC Names Elhedery CEO, Picking Insider for Top Job Supreme was founded in New York by James Jebbia in 1994, selling clothes and footwear targeting skateboarding and urban trends. It has moved from being a cult favorite, with its distinct red and white logo, to a mainstream success and now has an online business as well as 17 stores in the US, Asia and Europe. EssilorLuxottica shares traded 3% lower early Wednesday in Paris, trimming their year-on-year gain to 10%. VF was down 0.5% in premarket US trading. Jebbia said he supports the sale to Essilor as it will allow Supreme to focus on its brand, products and customers. Supreme’s growth has been fueled by so-called “hype” marketing, including limited-edition collaborations with partners ranging from watchmakers to musicians, and frequent “drops” of new products. Among others, it has tied up with Louis Vuitton and The North Face. VF acquired Supreme in 2020 as part of a $2.1 billion deal with private equity firm Carlyle Group and investors including Goode Partners. EssilorLuxottica was formed from the merger of two of Europe’s most prominent eyewear companies — Italy’s Luxottica and France’s Essilor. It is a global leader in the production and sale of prescription eyeglasses, sunglasses and contact lenses. Separately, EssilorLuxottica also said it’s buying a majority stake of 80% in Heidelberg Engineering — a German company that specializes in diagnostic solutions, digital surgical technologies and health-care IT for clinical ophthalmology. That agreement will boost EssilorLuxottica’s medical technology business, which sits alongside the fashion-focused arm selling sunglasses and accessories. --With assistance from Jennifer Creery. (Updates with VF acquisition, premarket shares) Most Read from Bloomberg Businessweek Top Takeaways From Businessweek’s Donald Trump Interview Why the Nobel-Laureate Pioneer of Microfinance Risks Life in Jail Interviewing Trump on His Plans for the US Economy Here’s How to Create a Social Safety Net With Bipartisan Support How Rivian Became the Anti-Tesla ©2024 Bloomberg L.P.
EssilorLuxottica to Buy Supreme Brand for $1.5 Billion
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...